↑ Sanofi Leveraging AI, Investing in Acquisitions, and Gaining Regulatory Approvals Amid Market Challenges
In a series of recent developments, Sanofi ceased the provision of its high cholesterol drug in China due to scarce availability. However,...
4 months ago